Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
motesanib + panitumumab
- Development stage
- Phase 2
- Lead developer
- Amgen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Motesanib + panitumumab is a combination therapy consisting of motesanib, an orally administered small-molecule antagonist of vascular endothelial growth factor receptors (VEGFR1, 2, and 3), platelet-derived growth factor receptor (PDGFR), and Kit, along with panitumumab, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody. This combination has been studied in clinical trials for advanced solid tumors, particularly in the context of cancer treatment regimens that may also include chemotherapy agents.
02
Targets
EGFR (Epidermal growth factor receptor)PDGFR (PDGFR family)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on motesanib + panitumumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on motesanib + panitumumab.